Key facts
- SecondWave’s last known valuation is $15.0M (Apr 2025).
- It has raised $7.0M; the latest was Later Stage VC ($7.0M) in Apr 2025.
- Notable investors include United States Department of War, Empire State Development, ARPA-H, Discovery Capital, Fogarty Innovation — 8 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 8 names
- ·Watchlist + deal alerts for SecondWave
- ·The full record, as it builds
Funding rounds
No funding rounds for SecondWave are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About SecondWave
Developer of a clinical-stage medical device designed for treating debilitating or life-threatening diseases. The company's devices use low-intensity focused ultrasound (LiFU) to modulate nerves, cells, and organs deep within the body and provide physicians an alternative to treat illness, enabling patients and their physicians with cost-effective, personalized intervention for chronic conditions to avoid invasiveness.
- Sector
- Healthcare
- HQ
- Minneapolis, MN, United States
- Founded
- 2019
- Employees
- 12
- Website
- secondwaveus.com/
- Ownership
- Privately Held (backing)
SecondWave doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in SecondWave shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on SecondWave in its N-PORT filings yet. We sweep new filings monthly.